ESTA — Establishment Labs Holdings Inc
Is ESTA overbought or oversold? Here is the current MarketMoodz read.
Establishment Labs Holdings Inc (ESTA) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $69.51. The rating moved from Neutral to Overbought on November 7, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$69.51
- Last changeMoved from Neutral to Overbought on November 7, 2026
- SectorHealthcare
- IndustryMedical Devices
See all overbought Healthcare stocks →
AI analysis
Establishment Labs is positioned in a specialized aesthetic device niche with product differentiation and international growth potential that support above-current valuation in a constructive market backdrop. Short-term performance will depend on procedure volumes, distribution execution and any product/regulatory headlines; limited analyst coverage and elective-demand cyclicality increase volatility risk. With execution on channel expansion and maintaining manufacturing/regulatory discipline, the company can demonstrate durable revenue growth, but near-term downside remains tied to litigation, quality or macro softness.
Key factors
- Niche leadership in aesthetic breast implant/implantable-device category with differentiated product features that support premium pricing and surgeon preference
- Exposure to secular tailwinds in elective aesthetic procedures and international markets where procedure volume growth is stronger
- Distribution and channel expansion opportunities (specialty clinics, international distributors) that can scale revenue without proportional fixed-cost increases
- Product upgrade cycle and potential recurring revenue from proprietary consumables, services, and technology-enabled offerings
- Limited near-term macro/policy headwinds in the market summary; subdued volatility supports measured investor interest in growth/healthcare names
Risks
- Regulatory scrutiny and product-related litigation risk inherent to implantable devices (historical implant litigation is a relevant precedent)
- Elective-procedure demand is cyclical and sensitive to macroeconomic weakness, which can compress sales quickly in downturns
- Competition from incumbent medtech companies and new entrants with scale, distribution or lower-cost alternatives
- Manufacturing, quality-control or supply-chain disruptions that could impact shipments and reputation
- Limited public information / analyst coverage and uncertain social sentiment create visibility and liquidity constraints for investors
See today's live rating, score and targets
Members see the live hourly rating for ESTA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.